Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1581-1582

  Curi, Dany A ^a,b   Beauchamp, Elspeth M ^b   Platanias, Leonidas C ^b,c  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; HOMOHARRINGTONINE; IMATINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; BENZAMIDE DERIVATIVE; CHROMONE DERIVATIVE; KINESIN;

CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; HUMAN; MITOSIS INHIBITION; NOTE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TRANSFORMED CELL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; MITOSIS;

APOPTOSIS; BENZAMIDES; CHROMONES; DRUG RESISTANCE, NEOPLASM; HUMANS; KINESIN; MITOSIS;

EID: 84932164227     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.970549     Document Type: Note

References (21)

1. O' Hare T, Deninger MW, Eide CA, et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosomepositive leukemia. Clin Cancer Res 2011; 17: 212-221.
2. Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin B 2011; 1: 197-207.
3. Bixby DL. Managing inadequate responses to frontline treatment of chronic myeloid leukemia:A case-based review. Cancer Treat Rev 2013; 39: 241-251.
4. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 7519-7527.
5. Goldman J M, Melo J V. C hronic myeloid leukemia- Advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
6. Lange T, Park B, Willis SG, et al. BCR-ABL kinase domain mutations in chronic myeloid leukemia not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005; 4: 1761-1766.
7. Agarwal MB, Rathi SA. Will kinase domain mutations dictate the terms. Indian J Med Paediatr Oncol 2013; 34: 151-153.
8. Marin D, Bazeos A, Mahon F X, et al. A dherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
9. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-3736.
10. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35: 1347-1351.
11. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
12. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
13. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region- Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010; 53: 4701-4719.
14. O' Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
15. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.
16. National Cancer Institue. FDA approval for ponatinib hydrochloride. Available from: www.cancer.gov/cancertopics/ druginfo/fda-ponatinibhydrochloride
17. Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Design 2011; 17: 59-64.
18. National Cancer Institute. FDA approval for omacetaxine mepesuccinate. Available from: www.cancer.gov/cancertopics/ druginfo/fda-omacetaxinemepesuccinate
19. Quint á s-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009: 115: 5382-5393.
20. Yin Y, Sun H, Xu J, et al. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells. Leuk Lymphoma 2015; 56: 1813-1820.
21. Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008; 14: 7583-7587.